Stock AnalizAscendis Pharma A ASND
Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026
Ascendis Pharma A (ASND) is a healthcare company listed in the US with a market value of about $18.1B. In the twelve months to September 30, 2026 it had revenue of $1.3B and net income of $966M, a net margin of 72.9%.
Its overall Stock Analiz score is 2.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is shareholder returns (0/5).
Key numbers: a P/E of 18.6, a price to free cash flow of 31.7, 5-year revenue growth of 151% a year, a 5-year average ROIC of -47%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 63% below the current price.
Score: 2.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- Interest covered more than 5 times
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3B | $846M | $378M | $295M | $55M | $9M | $9M | $15M | $12M | $2M | $5M |
| Net income | $966M | -$268M | -$393M | -$532M | -$622M | -$434M | -$514M | -$245M | -$149M | -$149M | -$72M |
| Free cash flow | $572M | — | — | -$519M | -$544M | -$500M | -$358M | -$203M | -$162M | -$115M | -$64M |
| EPS (diluted) | $14.78 | $-4.07 | $-5.96 | $-8.07 | $-9.44 | $-6.59 | $-7.80 | $-3.72 | $-2.26 | $-2.26 | $-1.10 |
| Net margin | 72.9% | -31.7% | -104.0% | -180.5% | -1139.6% | -4931.6% | -6025.5% | -1630.0% | -1229.5% | -8097.8% | -1487.3% |
| ROIC | — | -16.5% | -30.7% | -74.3% | -67.0% | -45.7% | -39.4% | -37.9% | -55.1% | -59.4% | -41.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Ascendis Pharma A’s P/E ratio?
About 18.6, based on the last twelve months of diluted earnings per share (forward P/E about 22.7).
Is Ascendis Pharma A stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 63% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Ascendis Pharma A pay a dividend?
Not currently.
Is Ascendis Pharma A a good stock to buy?
We do not give buy or sell advice. Ascendis Pharma A scores 2.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.